COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

NCT05268601 · clinicaltrials.gov ↗

COMPLETED

Status

251

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Bamlanivimab
DRUG: Bamlanivimab and Etesevimab Drug Combination
DRUG: Casirivimab and Imdevimab Drug Combination
DRUG: Sotrovimab

Sponsor

University of Milano Bicocca